I was pleased to see a new blog post today from my former colleague, Amy Adams, who now works at the California Institute for Regenerative Medicine. Amy tackles the evolving understanding of the therapeutic potential of induced pluripotent stem cells, or iPS cells, that can be generated from a variety of adult tissues. She draws from a recent story in USA Today, which summarizes the research from the past few years, while also putting a uniquely CIRM-focused spin on it. The conclusion? It's too early to tell whether these cells will be good substitutes for embryonic stem cells, or if they cling too tenaciously to their former identity to be useful for therapies.
Amy's take on the subject is smart and funny - just like her. Check it out.
Previously: Interactive timeline of iPS cell research
